Simplicity Wealth LLC Purchases New Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Simplicity Wealth LLC acquired a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,166 shares of the medical instruments supplier’s stock, valued at approximately $857,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in WST. Quarry LP lifted its stake in West Pharmaceutical Services by 155.3% in the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Northwest Investment Counselors LLC acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $40,000. Planned Solutions Inc. bought a new stake in West Pharmaceutical Services during the 4th quarter worth $39,000. Addison Advisors LLC increased its holdings in West Pharmaceutical Services by 37.9% in the 3rd quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 39 shares in the last quarter. Finally, Opal Wealth Advisors LLC bought a new position in West Pharmaceutical Services in the first quarter valued at about $74,000. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Down 3.6 %

Shares of WST traded down $12.86 during trading hours on Monday, hitting $342.78. The stock had a trading volume of 668,064 shares, compared to its average volume of 524,993. The firm has a 50 day simple moving average of $378.07 and a 200-day simple moving average of $364.28. West Pharmaceutical Services, Inc. has a 1-year low of $310.42 and a 1-year high of $415.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. The firm has a market capitalization of $24.97 billion, a P/E ratio of 45.22, a price-to-earnings-growth ratio of 6.28 and a beta of 1.05.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The firm had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. During the same quarter in the previous year, the company posted $1.98 earnings per share. The company’s quarterly revenue was down 3.0% on a year-over-year basis. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.23%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s dividend payout ratio is currently 10.55%.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of research reports. KeyCorp raised their price objective on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a report on Tuesday, February 13th. StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, February 16th. UBS Group lowered their price objective on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research report on Friday, February 16th. Finally, Jefferies Financial Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their target price for the company from $323.00 to $536.00 in a research report on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $435.20.

Read Our Latest Analysis on WST

Insider Transactions at West Pharmaceutical Services

In other news, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Silji Abraham sold 7,012 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $365.00, for a total transaction of $2,559,380.00. Following the completion of the sale, the senior vice president now owns 4,660 shares of the company’s stock, valued at approximately $1,700,900. The disclosure for this sale can be found here. Insiders sold a total of 139,978 shares of company stock valued at $50,852,672 over the last three months. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.